

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<http://www.daiichisankyo.com>

Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2016

TOKYO, Japan (February 24, 2016) – Daiichi Sankyo Company, Limited, today announced the following organizational changes taking place from April 1, 2016.

1. Daiichi Sankyo Co., Ltd.

(1) Research & Development Division

With the intent to increase our focus in the area of Oncology and speed up our drug development/discovery process, the following structural changes will take place:

① Oversight Structure/Organization

The current Research, Biologics, and Development Functions will separate out their oncology-related research and clinical development functions respectively into the newly established Oncology Function. In addition, the Research Technology Function, which will create and enhance the technology platform, will also be created. Biologics-related functions will be moved under both of these functions, as well as the Pharmaceutical Technology Division, and the Biologics Function will be dissolved.

② Research Structure/Organization

Aiming to speed up drug discovery research, laboratory organizations' disparate functions/therapeutic areas will be restructured based on focused therapeutic areas. Single organization for each focusing therapeutic area will be organized, managing medicinal chemistry, pharmacology research and external research and technology alliance under single decision making point. Further, pursuing new opportunities to deliver more innovative drugs, "Cell therapy Laboratory" will be established. This laboratory collaborates with "Regenerative Medicine Field" in Asubio Pharma Co., Ltd.

In Research Technology Function, the Modality Research Laboratories which will focus specialization on functions that discover next generation drug candidates such as the peptide drug, protein drug, nucleic-acids medicine, and in Oncology Function, Oncology Laboratories which will focus oncology research and the Biologics & Immuno-Oncology Laboratories which will focus oncology-related biologics research functions will be created.

<New/Restructured Organizations>

- ◆ Within the Research Function
 - Pain & Neuroscience Laboratories
 - End-Organ Disease Laboratories
 - Rare Disease & LCM Laboratories
 - Cell Therapy Laboratories

- ◆ Within the Research Technology Function
 - Drug Metabolism & Pharmacokinetics Research Laboratories
 - Medicinal Safety Research Laboratories
 - Modality Research Laboratories

- ◆ Within the Oncology Function
 - Oncology Laboratories
 - Biologics & Immuno-Oncology Laboratories

<Dissolved Organizations>

- ◆ Medicinal Chemistry Research Laboratories
- ◆ Oncology Research Laboratories
- ◆ Cardiovascular-Metabolics Research Laboratories
- ◆ Frontier Research Laboratories
- ◆ Biological Research Laboratories
- ◆ Biologics Pharmacology Research Laboratories
- ◆ New Modality Research Laboratories

③ **Development Organizations**

The Development Planning, Clinical Execution, as well as the Translational Medicine & Clinical Pharmacology Departments will be reorganized, consolidating the functions for clinical development of oncology area into the Oncology Clinical Development Department, and the areas outside of Oncology under the Clinical Development Department.

<New/Restructured Organizations>

- ◆ Within the Development Function
 - Clinical Development Department
- ◆ Within the Oncology Function
 - Oncology Clinical Development Department

<Dissolved Organizations>

- ◆ Development Planning Department
- ◆ Clinical Execution Department

(2) **Pharmaceutical Technology Division**

The Biologics Technology Research Laboratories, an affiliate of the Research & Development Division, will be moved under the Pharmaceutical Technology Division, enhancing manufacturing technology for commercial production as biologics project moves to the late stage.

<New/Restructured Organizations>

- ◆ Under the Pharmaceutical Technology Division
 - Biologics Technology Research Laboratories

(3) **Medical Affairs Division**

Independent from the Sales organization, a Medical Affairs Division will be established in order to maximize the value of company's products, providing information around therapeutic areas and medical strategy plans based on medical/scientific/ethical value judgments. Related functions dissolved from each area of the current organization will be consolidated within this Division, establishing the Medical Science Department, (which will assume the functions of generating/providing information and general Division planning and external affairs), in conjunction with moving the Medical Information Department out from under the Sales & Marketing Division.

<New/Restructured Organizations>

- ◆ Under the Medical Affairs Division
 - Medical Science Department
 - Medical Information Department